Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SK-09

Phase 1Small molecule

CConsun Pharmaceutical Group

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

FSGSRecruiting

FSGSPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

FSGS

NCT07267026

Clinical

Trials by Indication[1]

FSGS1 trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of SK-09 in Healthy Adult Participants

Recruiting·CConsun Pharmaceutical Group·Phase 1·NCT07267026·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SK-09. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SK-09 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SK-09. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Consun Pharmaceutical Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CConsun Pharmaceutical Group

Related News